Amit J. Sabnis

Hematology | Oncology
1825 4th St
San Francisco, CA 94143

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications

In vivo manipulation of the protein homeostasis network in rhabdomyosarcoma.

In vivo manipulation of the protein homeostasis network in rhabdomyosarcoma.

Journal: Oncotarget
Published: August 29, 2025

Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial.

Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial.

Journal: JCO precision oncology
Published: June 27, 2024

The essential chaperone DNAJC17 activates HSP70 to coordinate RNA splicing and G2-M progression.

The essential chaperone DNAJC17 activates HSP70 to coordinate RNA splicing and G2-M progression.

Journal: bioRxiv : the preprint server for biology
Published: November 14, 2023

The essential chaperone DNAJC17 activates HSP70 to coordinate RNA splicing and G2-M progression.

The essential chaperone DNAJC17 activates HSP70 to coordinate RNA splicing and G2-M progression.

Journal: Scientific reports
Published: June 30, 2023

Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma.

Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma.

Journal: JCO precision oncology
Published: March 30, 2023

Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer.

Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer.

Journal: JCO precision oncology
Published: November 29, 2022

GATOR2-dependent mTORC1 activity is a therapeutic vulnerability in FOXO1 fusion-positive rhabdomyosarcoma.

GATOR2-dependent mTORC1 activity is a therapeutic vulnerability in FOXO1 fusion-positive rhabdomyosarcoma.

Journal: JCI insight
Published: May 27, 2022

Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).

Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).

Journal: Neuro-oncology
Published: April 08, 2022

Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer.

Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer.

Journal: Nature medicine
Published: September 29, 2021

Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor.

Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor.

Journal: JCO precision oncology
Published: June 23, 2021

Clinical characteristics and outcomes of infants compared with children diagnosed with rhabdomyosarcoma: Analysis of surveillance, epidemiology and end results data from 2000 to 2016.

Clinical characteristics and outcomes of infants compared with children diagnosed with rhabdomyosarcoma: Analysis of surveillance, epidemiology and end results data from 2000 to 2016.

Journal: Cancer reports (Hoboken, N.J.)
Published: April 08, 2021

Germline MUTYH Mutation in a Pediatric Cancer Survivor Developing a Secondary Malignancy.

Germline MUTYH Mutation in a Pediatric Cancer Survivor Developing a Secondary Malignancy.

Journal: Journal of pediatric hematology/oncology
Published: December 10, 2019
Showing 1-12 of 29

Last Updated: 09/26/2026